In Vitro Diagnostics - France | Statista Market Forecast

The projected revenue in the In Vitro Diagnostics market market in France is estimated to reach US$2.62bn by 2024.
It is expected that the revenue will experience an annual growth rate (CAGR 2024-2029) of 1.96%, leading to a market volume of US$2.88bn by 2029.
When compared globally, the United States is anticipated to generate the highest revenue, amounting to US$30.10bn in 2024.
France has seen a surge in demand for in vitro diagnostics, driven by the country's strong healthcare infrastructure and focus on preventive medicine.

Definition:
The market In Vitro Diagnostics (IVD) consists of medical instruments and accessories used to perform tests with the help of biological samples. In Vitro Diagnostics provide valuable information used for detection, prognosis, prevention, and therapeutic monitoring of diseases.

Additional information:
Market values represent revenues paid to primary vendors at manufacturer price level either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), enterprises (B2B) as well as governments (B2G). Revenues are allocated to the country where the money is spent.

Company examples: Roche Diagnostics, Abbott Laboratories, Danaher, Siemens Healthineers.
Further information on the key players can be found in the Market Shares boxes.

Molecular diagnosis
Immunoassays
Clinical chemistry
Microbiology
Hematology

Services (i.e., treatment expenses)
Imaging diagnostics

The In Vitro Diagnostics market in France is experiencing significant growth and development due to several factors.

Customer preferences: Customers in the In Vitro Diagnostics market in France are increasingly seeking more accurate and reliable diagnostic tests. They are also demanding faster turnaround times for test results and a wider range of tests that can be performed. Additionally, there is a growing preference for non-invasive diagnostic tests that minimize patient discomfort and improve overall patient experience.

Trends in the market: One of the key trends in the In Vitro Diagnostics market in France is the increasing adoption of molecular diagnostics. This technology allows for the detection and analysis of genetic material, enabling more precise and personalized diagnoses. The use of molecular diagnostics is particularly prevalent in the field of oncology, where it is used to identify specific genetic mutations and guide targeted therapies. Another trend is the growing demand for point-of-care testing, which allows for rapid and convenient diagnostic testing at the patient's bedside or in a physician's office. This trend is driven by the need for faster diagnosis and treatment decisions, especially in emergency situations.

Local special circumstances: France has a well-established healthcare system, which includes a strong network of hospitals, clinics, and laboratories. This infrastructure supports the growth of the In Vitro Diagnostics market by providing the necessary facilities and expertise for diagnostic testing. Additionally, France has a high prevalence of chronic diseases such as cardiovascular diseases, diabetes, and cancer, which further drives the demand for diagnostic tests. The country also has a large aging population, which increases the need for diagnostic tests and monitoring of chronic conditions.

Underlying macroeconomic factors: The In Vitro Diagnostics market in France is influenced by several macroeconomic factors. The country has a stable economy with a high level of healthcare expenditure, which supports the development and adoption of advanced diagnostic technologies. The French government also plays a significant role in the healthcare sector, providing funding and incentives for research and development in the field of diagnostics. Additionally, France is home to several leading diagnostic companies and research institutions, which contribute to the innovation and growth of the market. In conclusion, the In Vitro Diagnostics market in France is experiencing growth and development due to customer preferences for more accurate and convenient diagnostic tests. The increasing adoption of molecular diagnostics and point-of-care testing are key trends driving the market. France's well-established healthcare system, high prevalence of chronic diseases, and stable economy are local special circumstances that support the growth of the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on medical devices and IVD revenues allocated to the country where the money is spent at manufacturer price levels excluding VAT.

Modeling approach / Market size:

Modeling employs a top-down approach with a bottom-up validation, using financial information of the key players by market. Market sizes are determined by a top-down approach, based on a specific rationale for each market market and allocated to the covered countries according to the global market shares. As a basis for evaluating markets, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare system, and regulations concerning medical products. Next, we use further relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare payer system, and regulations concerning medical products. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Medical technology plays a role in the lives of everyone. It includes most of all, medical devices which simplify the prevention, diagnosis, and treatment of diseases and illnesses. The most well-known medical technology products are, among others, pacemakers, imaging instruments, dialysis machines, and implants. The global medical technology industry was worth over 567 billion U.S. dollars annually. Established centers of this industry include North America and Western Europe. The United States is home to the world’s largest medical technology companies. As of 2022, Abbott Laboratories had the largest global revenue at over 31.2 billion U.S. dollars. The main focus of devices manufactured by the Chicago-based company are diagnostics, cardiovascular, and diabetes care. Two other medtech companies that round off the top three largest companies –Medtronic and Johnson & Johnson – are both based in the United States. Although, industry trends show that Asia, and in particular China, is about to play a more prominent role in the years to come.